IL-1 blockade in autoinflammatory syndromes
- PMID: 24422572
- PMCID: PMC4178953
- DOI: 10.1146/annurev-med-061512-150641
IL-1 blockade in autoinflammatory syndromes
Abstract
Monogenic autoinflammatory syndromes present with excessive systemic inflammation including fever, rashes, arthritis, and organ-specific inflammation and are caused by defects in single genes encoding proteins that regulate innate inflammatory pathways. Pathogenic variants in two interleukin-1 (IL-1)-regulating genes, NLRP3 and IL1RN, cause two severe and early-onset autoinflammatory syndromes, CAPS (cryopyrin associated periodic syndromes) and DIRA (deficiency of IL-1 receptor antagonist). The discovery of the mutations that cause CAPS and DIRA led to clinical and basic research that uncovered the key role of IL-1 in an extended spectrum of immune dysregulatory conditions. NLRP3 encodes cryopyrin, an intracellular "molecular sensor" that forms a multimolecular platform, the NLRP3 inflammasome, which links "danger recognition" to the activation of the proinflammatory cytokine IL-1β. The success and safety profile of drugs targeting IL -1 in the treatment of CAPS and DIRA have encouraged their wider use in other autoinflammatory syndromes including the classic hereditary periodic fever syndromes (familial Mediterranean fever, TNF receptor-associated periodic syndrome, and hyperimmunoglobulinemia D with periodic fever syndrome) and additional immune dysregulatory conditions that are not genetically well defined, including Still's, Behcet's, and Schnitzler diseases. The fact that the accumulation of metabolic substrates such as monosodium urate, ceramide, cholesterol, and glucose can trigger the NLRP3 inflammasome connects metabolic stress to IL-1β-mediated inflammation and provides a rationale for therapeutically targeting IL-1 in prevalent diseases such as gout, diabetes mellitus, and coronary artery disease.
Figures
Similar articles
-
Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1.Clin Exp Immunol. 2012 Mar;167(3):391-404. doi: 10.1111/j.1365-2249.2011.04533.x. Clin Exp Immunol. 2012. PMID: 22288582 Free PMC article. Review.
-
[CAPS: cryopyrin-associated periodic syndrome].Nihon Rinsho Meneki Gakkai Kaishi. 2011;34(5):369-77. doi: 10.2177/jsci.34.369. Nihon Rinsho Meneki Gakkai Kaishi. 2011. PMID: 22041424 Review. Japanese.
-
Treating inflammation by blocking interleukin-1 in humans.Semin Immunol. 2013 Dec 15;25(6):469-84. doi: 10.1016/j.smim.2013.10.008. Epub 2013 Nov 23. Semin Immunol. 2013. PMID: 24275598 Free PMC article. Review.
-
Immunology in clinic review series; focus on autoinflammatory diseases: role of inflammasomes in autoinflammatory syndromes.Clin Exp Immunol. 2012 Mar;167(3):382-90. doi: 10.1111/j.1365-2249.2011.04535.x. Clin Exp Immunol. 2012. PMID: 22288581 Free PMC article. Review.
-
Cryopyrin-associated periodic syndromes: diagnosis and management.Paediatr Drugs. 2012 Apr 1;14(2):109-17. doi: 10.2165/11595040-000000000-00000. Paediatr Drugs. 2012. PMID: 22335455 Review.
Cited by
-
Single Center-Based Real-World Experience on Anti-IL 1 Biological Response Modifiers: A Case Series and Literature Review.Children (Basel). 2024 Sep 22;11(9):1146. doi: 10.3390/children11091146. Children (Basel). 2024. PMID: 39334678 Free PMC article.
-
Inflammatory turmoil within: an exploration of autoinflammatory disease genetic underpinnings, clinical presentations, and therapeutic approaches.Adv Rheumatol. 2024 Aug 22;64(1):62. doi: 10.1186/s42358-024-00404-9. Adv Rheumatol. 2024. PMID: 39175060 Review.
-
Pharmacological Analysis of NLRP3 Inflammasome Inhibitor Sodium [(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl][(1-methyl-1H-pyrazol-4-yl)({[(2S)-oxolan-2-yl]methyl})sulfamoyl]azanide in Cellular and Mouse Models of Inflammation Provides a Translational Framework.ACS Pharmacol Transl Sci. 2024 Apr 18;7(5):1438-1456. doi: 10.1021/acsptsci.4c00061. eCollection 2024 May 10. ACS Pharmacol Transl Sci. 2024. PMID: 38751618
-
Vaccines Induce Homeostatic Immunity, Generating Several Secondary Benefits.Vaccines (Basel). 2024 Apr 9;12(4):396. doi: 10.3390/vaccines12040396. Vaccines (Basel). 2024. PMID: 38675778 Free PMC article. Review.
-
Inflammasome Molecular Insights in Autoimmune Diseases.Curr Issues Mol Biol. 2024 Apr 18;46(4):3502-3532. doi: 10.3390/cimb46040220. Curr Issues Mol Biol. 2024. PMID: 38666950 Free PMC article. Review.
References
-
- McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999;97:133–44. - PubMed
-
- The International FMF Consortium Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 1997;90:797–807. - PubMed
-
- The French FMF Consortium A candidate gene for familial Mediterranean fever. Nat. Genet. 1997;17:25–31. - PubMed
-
- McGonagle D, Aziz A, Dickie LJ, et al. An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum. Pediatr. Res. 2009;65:38R–45R. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous